Gilead Sciences Inc (GILD34)

Currency in BRL
323.11
0.00(0.00%)
Delayed Data·
GILD34 Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
GILD34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
323.11323.11
52 wk Range
197.78345.65
Key Statistics
Bid/Ask
318.11 / 319.04
Prev. Close
323.11
Open
323.11
Day's Range
323.11-323.11
52 wk Range
197.78-345.65
Volume
8
Average Volume (3m)
107
1-Year Change
49.66%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GILD34 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Gilead Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Gilead Sciences Inc Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Employees
17600
Market
Brazil

Compare GILD34 to Peers and Sector

Metrics to compare
GILD34
Peers
Sector
Relationship
P/E Ratio
24.2x−2.8x−0.5x
PEG Ratio
0.020.040.00
Price/Book
7.5x1.3x2.6x
Price / LTM Sales
5.0x58.0x3.2x
Upside (Analyst Target)
-292.1%41.6%
Fair Value Upside
Unlock6.9%6.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.78%
Dividend Yield
1.80%
Industry Median 2.70%
Annualised payout
5.83
Paid quarterly
5-Years Growth
+3.82%
Growth Streak

Earnings

Latest Release
May 07, 2025
EPS / Forecast
1.04 / --
Revenue / Forecast
6.67B / --
EPS Revisions
Last 90 days

GILD34 Income Statement

FAQ

What Stock Exchange Does Gilead Sciences DRC Trade On?

Gilead Sciences DRC is listed and trades on the B3 Stock Exchange stock exchange.

What Is the Stock Symbol for Gilead Sciences DRC?

The stock symbol for Gilead Sciences DRC is "GILD34."

What Is the Gilead Sciences DRC Market Cap?

As of today, Gilead Sciences DRC market cap is 796.50B.

What Is Gilead Sciences DRC's Earnings Per Share (TTM)?

The Gilead Sciences DRC EPS (TTM) is 4.78.

From a Technical Analysis Perspective, Is GILD34 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Gilead Sciences DRC Stock Split?

Gilead Sciences DRC has split 0 times.

How Many Employees Does Gilead Sciences DRC Have?

Gilead Sciences DRC has 17600 employees.

What is the current trading status of Gilead Sciences DRC (GILD34)?

As of 28 Jul 2025, Gilead Sciences DRC (GILD34) is trading at a price of 323.11, with a previous close of 323.11. The stock has fluctuated within a day range of 323.11 to 323.11, while its 52-week range spans from 197.78 to 345.65.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.